Precise Therapy for Patients With AML: Experts Discuss Clinical Challenges and Future Directions

Sign up now! Registration is complimentary. 

Radisson Blu Aqua Hotel

Route 12 (Drop off at the Hyatt Regency; Gate 31: East Bldg near Arie Crown Theater)

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.


Pre-registration is now closed. We welcome you to register on-site at the Radisson Blu Aqua Hotel (221 N Columbus Drive), Atlantic Ballroom A at 6:30 PM. Remember to bring your ASCO Annual badge to expedite your registration.

7:00 PM Program Overview

7:05 PM Biological Markers for Predicting Outcomes in AML

7:20 PM Case Discussion 1: Targeting Antigens in AML—New Advances in Antibody–Drug Conjugates and Other Antibody-Based Therapies

7:40 PM Case Discussion 2: Overcoming Treatment Challenges in Patients With Newly Diagnosed AML

8:05 PM Case Discussion 3: Available and Emerging Treatment Options in FLT3-Mutant AML

8:20 PM Case Discussion 4: Available and Emerging Treatment Options in IDH-Mutant AML

8:40 PM Exploring New Therapeutic Frontiers in AML—What Are the Emerging Molecular Targets?

8:50 PM Closing Remarks and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Farhad Ravandi, MD

Professor of Medicine
Section of Developmental Therapeutics
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ellen Ritchie, MD

Associate Professor
Division of Hematology and Oncology
Department of Medicine
Weill Cornell Medical College
New York, New York


Hematologic Oncologist
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in selecting and safely integrating BTK inhibitors within the current treatment paradigm for various B-cell malignancies considering patient-specific and prognostic factors as well as appropriate dosing and strategies to manage treatment-emergent adverse events.

Target Audience
This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with MCL, CLL, and other B-cell malignancies.

Learning Objectives 

  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, and therapeutic decisions
  • Assess the available evidence to optimally integrate antibody–drug conjugates and other antibody-based therapies in AML
  • Plan evidence-based therapeutic strategies using novel formulations and refinements of conventional chemotherapy
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations
  • Manage treatment-related toxicities associated with novel therapeutics
  • Identify patients with AML who may benefit from enrollment on clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.